Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?

Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?

Neil Klompas Biography and Net Worth

CFO of Zymeworks

Mr. Klompas joined Zymeworks in March 2007 and currently serves as our Chief Operating Officer. Mr. Klompas served as Zymeworks’ Chief Financial Officer from 2007 to 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the Board of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia. He serves on the faculty advisory board for Biotechnology and Chemistry for Camosun College and as a member of the board of directors of Ovensa Inc., a private biotechnology company.

What is Neil A. Klompas' net worth?: The estimated net worth of Neil A. Klompas is at least $262,122.48 as of March 10th, 2023. Mr. Klompas owns 17,032 shares of Zymeworks stock worth more than $262,122 as of November 15th. This net worth evaluation does not reflect any other investments that Mr. Klompas may own. Learn More about Neil A. Klompas' net worth.
How do I contact Neil A. Klompas?: The corporate mailing address for Mr. Klompas and other Zymeworks executives is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Neil A. Klompas' contact information.
Has Neil A. Klompas been buying or selling shares of Zymeworks?: Neil A. Klompas has not been actively trading shares of Zymeworks in the last ninety days. Most recently, Neil A. Klompas sold 2,977 shares of the business's stock in a transaction on Friday, March 10th. The shares were sold at an average price of $7.83, for a transaction totalling $23,309.91. Following the completion of the sale, the chief operating officer now directly owns 17,032 shares of the company's stock, valued at $133,360.56. Learn More on Neil A. Klompas' trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Neil Josephson (Insider), Neil Klompas (CFO), Kathryn O'Driscoll (Insider), James Priour (Insider), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 40,583 shares worth more than $436,263.55. The most recent insider tranaction occured on January, 8th when CFO Christopher Astle sold 1,431 shares worth more than $16,055.82. Insiders at Zymeworks own 1.9% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/8/2024.

Neil A. Klompas Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2023	Sell	2,977	$7.83	$23,309.91	17,032
3/10/2022	Sell	2,979	$6.88	$20,495.52
3/10/2021	Sell	1,425	$34.95	$49,803.75	11,896
12/9/2020	Sell	25,000	$53.25	$1,331,250.00	17,502
5/6/2019	Sell	8,308	$19.23	$159,762.84

Neil A. Klompas Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Today's Range

Now: $15.39

$15.00

$16.24

50 Day Range

MA: $13.51

$11.70

$17.40

2 Week Range

Now: $15.39

$7.54

$17.70

Volume

627,915 shs

Average Volume

625,659 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

5 Stocks that could triple in a week

From Traders Agency | Ad

Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.

Click here to pay just $5 for a full year of Stealth Trades